VASCERN COVID-19 Recommendations
With the current global spread of the novel coronavirus SARS Cov-2, causing COVID-19, the experts from the Rare Disease Working Groups of VASCERN have prepared the following consensus statements for patients with rare vascular diseases. These statements will be updated as necessary.
Hereditary Haemorrhgic Telangiectasia (HHT)
Heritable Thoracic Aortic Diseases (HTAD)
This statement can equally be found in:
Dutch: VASCERN HTAD verklaring over Covid 19
German: VASCERN Erklärung zu Covid 19
Maltese: Stqarrija mill-VASCERN HTAD WG dwar il-COVID-19
Spanish: Declaración de VASCERN HTAD sobre Covid 19
Pediatric and Primary Lymphedema (PPL)
- The Pediatric and Primary Lymphedema (PPL) Working Group endorses the COVID-19 statement by the Lymphoedema Support Network
German translation available here
Medium sized Arteries (MSA)
Vascular Anomalies (VASCA)
- VASCERN Vascular Anomalies (VASCA) Working Group COVID-19 Statement– initiated by the patient advocacy groups in Europe and the United States and their medical advisory teams and approved by the VASCA WG.
This statement can equally be found in:
French: Information COVID-19 pour les patients porteurs d’ Anomalies Vasculaires et/ou Lymphatiques
[cq_vc_accordion][/cq_vc_accordion]